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Abstract
In regenerative medicine, new approaches are required for the creation of tissue substitutes, and the interplay between different 
research areas, such as tissue engineering, microsurgery and gene therapy, is mandatory. In this article, we report a modification of 
a published model of tissue engineering, based on an arterio-venous loop enveloped in a cross-linked collagen–glycosaminoglycan 
template, which acts as an isolated chamber for angiogenesis and new tissue formation. In order to foster tissue formation within 
the chamber, which entails on the development of new vessels, we wondered whether we might combine tissue engineering 
with a gene therapy approach. Based on the well-described tropism of adeno-associated viral vectors for post-mitotic tissues, 
a muscular flap was harvested from the pectineus muscle, inserted into the chamber and transduced by either AAV vector 
encoding human VEGF165 or AAV vector expressing the reporter gene β-galactosidase, as a control. Histological analysis of the 
specimens showed that muscle transduction by AAV vector encoding human VEGF165 resulted in enhanced tissue formation, 
with a significant increase in the number of arterioles within the chamber in comparison with the previously published model. 
Pectineus muscular flap, transduced by adeno-associated viral vectors, acted as a source of the proangiogenic factor vascular 
endothelial growth factor, thus inducing a consistent enhancement of vessel growth into the newly formed tissue within the 
chamber. In conclusion, our present findings combine three different research fields such as microsurgery, tissue engineering and 
gene therapy, suggesting and showing the feasibility of a mixed approach for regenerative medicine.
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Introduction
Since the rise of tissue engineering, the development of 
biological substitutes in medical research has been a key 
issue in order to develop new strategies to replace lost or 
damaged tissues. The research field focused on new tissue 
formation is improving day by day, and it is nowadays fac-
ing the problem of poor tissue vascularization.1–4 The angi-
ogenic process, which takes place within the scaffolds, is 
adequate to allow cellular oxygen supply, whereas it might 
not be sufficient to sustain tissue survival. Thus, in order to 
improve tissue vascularization, several approaches are 
currently under investigations, such as the addition of 
angiogenic factors, the seeding of cells engineered for the 
production of growth factors within the scaffold or the 
development of microsurgical strategies. 
Focusing on the usage of factors, several attempts have 
already been developed by the use of one or more recom-
binant proteins either alone or in combination such as vas-
cular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF) or platelet-derived growth factor b 
(PDGF-b) leading to promising results that were shown to 
be affected by the short half-life of the recombinant fac-
tors.5 Therefore, studies aimed to control the protein 
release from the scaffold, for instance by the application of 
slow release devices or modified matrix, were developed 
and led to better results suggesting that these approaches 
might be feasible.6–10 Moreover, concerning the microsur-
gical techniques, a promising approach has been devel-
oped by Morrison, who has combined tissue engineering 
and microsurgery.11–13 Focusing on the development of 
innovative approaches to enhance the formation of new 
blood vessel and, most importantly, the generation of a 
vascularized new tissue within a scaffold, a novel promis-
ing method has been described, based on a microsurgical 
arterio-venous loop (AVL) embedded in a collagen-based 
matrix.14 In this model, the main driver for blood vessel 
formation has been identified in the shear stress within the 
vessels of the AVL.4
A research area that is nowadays opening a new scenario 
in the tissue engineering field is gene therapy, which might 
be combined with the previously described approaches to 
improve them and to overcome their limitations. The use of 
recombinant vectors for the production of secreted proteins 
is widely used in research,15–17 and clinical trials have 
already been performed, such as for the treatment of hae-
mophilia.18,19 Among the different viral vectors that have 
been used so far, recombinant adeno-associated viral 
(rAAV) ones are emerging as feasible candidates for gene 
therapy due to their appealing features. Of interest, they are 
able to transduce post-mitotic cells and are characterized by 
a high tropism for skeletal muscle. Moreover, rAAVs can 
persist in the transduced cells, leading to long-lasting pro-
tein expression. We herein suggest a modification of the 
novel microsurgically induced regeneration chamber with 
the insertion of a muscle flap, which can be transduced by 
rAAVs leading to the secretion of VEGF that eventually 
will induce an enhancement of the already documented 
creation of newly formed fibrovascular tissue inside the 
chamber.
Hence, we propose an approach that combines adeno-
associated viral (AAV)-based gene therapy, a collagen 
scaffold, the pectineus muscular flap and a microsurgical 
AVL. The pectineus muscular flap is, in the proposed 
model, inserted into the tissue chamber, presenting also the 
AVL, and injected with AAV vector encoding human 
VEGF165 (AAV-VEGF165) in order to induce the produc-
tion of VEGF inside the chamber that might improve the 
angiogenic process and might eventually foster the growth 
of the implant.
Material and methods
Animals
In all, 21 adult male Wistar rats, weighting 300–350 g, 
were used for this study. All procedures were carried out 
under general anaesthesia using Zoletil (Virbac, Carros, 
France) 40 mg/kg in combination with xylazine (Sigma 
Aldrich, St. Louis, MO, USA) 15 mg/kg intramuscularly 
(i.m.). During surgery and for the following 10 days, rats 
were treated with heparin in order to avoid the formation 
of thrombi within the AVL forming vessels. The animals 
were housed in single cages and fed ad libitum.
Animal care and treatment were conducted in conform-
ity with institutional guidelines in compliance with 
national and international laws and policies (EEC Council 
Directive 86/609, OJL 358, 12 December 1987) after insti-
tutional review board approval.
Generation of the collagen chamber
A previously described AVL model was modified:14 a vein 
graft was harvested from one groin and used as a micro-
vascular loop between the femoral artery and vein in the 
contralateral leg. End-to-side anastomoses were per-
formed with 11/0 nylon sutures on both recipient artery 
and vein. Then, the vein graft was harvested as long as 
possible (about 2.4 cm) to enhance angiogenesis from the 
loop; the previously described chamber was closed fold-
ing the template on itself and suturing its free margins 
together. As the template is enveloped by a silicone layer, 
the outer envelope of the chamber is silicone; this model 
of the chamber encloses the AVL and has been demon-
strated as a valid system for fostering neovascularization 
as well as new loose connective tissue formation. In order 
to test whether we were able to improve the formation of 
new tissue within the collagen chamber, we added an ele-
ment to this model, represented by a muscle flap. Skeletal 
muscle has already been shown to be efficiently trans-
duced by rAAVs. In order to preserve muscle integrity, we 
conceived a model of local muscle flap (pedicled), and 
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due to the anatomical location, we chose the pectineus 
muscle as the target tissue to be inserted into the chamber 
for rAAV transduction. The pectineus flap, comprising its 
proximal part and sizing mostly 1 cm, was elevated and 
left pedicled under microscope magnification. One or two 
delicate stitches were tied to fix the muscle to the collagen 
matrix and to avoid residual contraction. The dermal tem-
plate (INTEGRA™) was then folded on itself, maintain-
ing the outer silicon layer, and secured by some suture 
stitches as a sandwich including the loop and the muscular 
flap (Figure 1(A)).
Adult male Wistar rats were divided into three groups 
(n = 7 per group) according to the treatment (no muscle, 
AAV vector expressing the reporter gene β-galactosidase 
(AAV-LacZ) and AAV-VEGF165); the tissue chamber was 
created as previously described and the isolated muscular 
flap was injected with 50 µL of either a control AAV-LacZ 
or the human VEGF165 isoform (AAV-VEGF165) (Figure 
1(A)), and the chamber was then closed. The first group 
acted as control. After 30 days, dermal implants were 
excised and analysed to detect the formation of new tissue 
and the presence of vessels. A schematic representation of 
the experimental flow chart is reported in Figure 1(B).
Recombinant AAV vectors
The rAAV vectors used in this study were produced by the 
AAV Vector Unit (AVU) at ICGEB Trieste (http://www.
icgeb.org/avu-core-facility.html), according to the estab-
lished procedures.20–22 AAV2 vectors are used in this study, 
due to serotype tropism for skeletal muscles, and they express 
either VEGF165 or β-galactosidase complementary DNA 
(cDNA) under the control of the constitutive cytomegalovi-
rus (CMV) immediate early promoter. All the viral stocks 
used had a titre ⩾ 1 × 1012 viral genome particles/mL. A sche-
matic representation of rAAVs is reported in Figure 1(C).
Histochemistry, immunofluorescence and 
morphometric analysis
On day 30, tissue chambers were harvested, following the 
previously described techniques.14 Briefly, rats were anaes-
thetized, the chambers were exposed, vessels were ligated 
proximally and distally and the specimens were harvested 
and immediately fixed in 10% formalin and embedded in 
paraffin. The 5-µm histological sections were stained with 
Azan trichrome staining (BioOptica, Milan, Italy) or 
Figure 1. Creation of a tissue chamber, based on an arterio-venous loop (AVL), feasible for gene therapy. (A) Tissue chamber was 
created (inset a) and a pectineus muscular flap was inserted into the chamber. The muscle was injected with either AAV-LacZ or 
AAV-VEGF165 before closure of the chamber (inset b). (B) Schematic representation of the experimental flow chart. (C) Schematic 
representation of rAAVs used in the study (ITR: inverted terminal repeats). (D) Samples were harvested 30 days after surgery, DNA 
extracted and viral load quantified by real-time PCR (vgc: viral genome copies). Data are expressed as mean ± SEM. (E) Samples were 
harvested 30 days after surgery, RNA extracted and cDNA synthesized. Expression of the transgene was quantified by real-time PCR; 
hVEGF expression was not detectable (ND) in the control sample. Data are expressed as mean ± SEM. (F) Representative images of 
the tissue chamber sample stained for α-SMA (red); nuclei are counterstained with DAPI (blue) (insets a and b: AAV-LacZ and AAV-
VEGF165, respectively). Several α-SMA-positive vessels can be observed in the AAV-VEGF165 sample, suggesting the effect of VEGF165 
overexpression. Split α-SMA images from AAV-LacZ and AAV-VEGF165 samples are reported in insets c and d, respectively. Vessels 
are interspersed within the muscle fibres that can be identified as background signal. Scale bar = 50 µm. 
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processed for immunofluorescence. The following primary 
antibodies were used: Cy3-coniugated anti–alpha smooth 
muscle actin (α-SMA) primary antibody (clone 1A4; Sigma) 
diluted 1:200 in blocking buffer was used to label smooth 
muscle cells/pericytes and myofibroblats. Anti-vimentin (sc-
6260; Santa Cruz Biotechnology, Dallas, USA) diluted 1:50 
in blocking buffer was used to label fibroblasts, and heat-
induced antigen retrieval at pH 6 was performed; AlexaFluor 
594 anti-mouse antibody (Molecular Probes, Thermo Fisher 
Scientific, Whaltman, MA USA) diluted 1:500 in blocking 
buffer was used as secondary antibody. Fluorescein-labelled 
Lycopersicon esculentum Lectin (FL-1171; Vector 
Laboratories, Burlingame, CA, USA) diluted 1:100 in block-
ing buffer was used to label endothelial cells. 4′,6-diamidino-
2-phenylindole (DAPI) (Vectashield, Vector Laboratories, 
Burlingame, CA, USA) fluorescent staining was used to rec-
ognize cell nuclei. Images were acquired at room tempera-
ture with a DMLB upright fluorescence microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with a charge-
coupled device camera (CoolSNAP CF; Roper Scientific, 
Trenton, NJ, USA) using MetaView 4.6 quantitative analysis 
software (MDS Analytical Technologies, Toronto, Canada). 
Images from Azan trichrome–stained sections were acquired 
by Leica Laser Microdissector LMD7000 (Leica 
Microsystems) equipped with a three charge-coupled device 
colour Hitachi HV-C20A camera (Hitachi, Tokyo, Japan) 
using Leica IM 1000 software (Leica Microsystems). For the 
quantification of the tissue within the chamber, the whole 
area occupied by the stained tissue was quantified by the use 
of ImageJ software. For the quantification of vessel number, 
at least 10 fields for each section were analysed. Relative 
areas occupied by differently stained cells were quantified by 
the use of ImageJ software.
DNA extraction and AAV detection within the 
tissue chamber
DNA was extracted from paraffin-embedded specimens, 
and five sections (50 µm) were deparaffinized, hydrated 
and digested with proteinase K. DNA content was quanti-
fied by means of the Qubit fluorometer (Invitrogen); 50 ng 
was subsequently used for AAV quantification performed 
by real-time polymerase chain reaction (PCR), using pre-
developed and custom-designed assays (Applied 
Biosystems, Thermo Fisher Scientific, Whaltman, MA, 
USA). Values are expressed as the number of viral genome 
copies (vgc) per microgram genomic DNA using an exter-
nal calibration curve. A list of the assays used is reported in 
Table 1. Amplifications were carried out in a CFX96 Real-
Time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA USA).
RNA isolation and transgene expression 
analysis
RNA was extracted from frozen samples using TriZol rea-
gent (Life Technologies, Thermo Fisher Scientific, 
Whaltman, MA, USA) and reversed transcribed using hex-
amerix random primers (Life Technologies, Thermo Fisher 
Scientific, Whaltman, MA, USA). The cDNA was subse-
quently used for transgene expression analysis performed 
by real-time PCR; the housekeeping gene hypoxanthine 
guanine phosphoribosyltransferase (HPRT) was used to 
normalize the results. A list of the assays used is reported 
in Table 1. Amplifications were carried out in a CFX96 
Real-Time PCR Detection System (Bio-Rad).
Statistics
Data are presented as mean ± standard error of the mean 
(SEM). Pair-wise comparison between groups was per-
formed using the Student’s t-test, whereas one-way analy-
sis of variance (ANOVA) and Bonferroni post hoc tests 
were used to compare multiple groups. A value of p < 0.05 
was considered statistically significant.
Results
Description of the model and detection of AAV 
within the tissue chamber
We herein propose a modification of a previously described 
AVL model by means of a gene therapy approach. In order 
to create an AVL, a vein graft was harvested from one groin 
Table 1. Assays used for real-time PCR.
Target Assay type Real-time probe Assay code or primer/probe sequences
hVEGF Pre-developed FAM Hs00173626_m1
HPRT Pre-developed VIC Rn01527840_m1
CMV Custom FAM Primer Fw 5′-TGGGCGGTAGGCGTGTA-3′
 Primer Rv 
5′-GATCTGACGGTTCACTAAACGAG-3′
 Probe 5′-CCTGGAGACGCCATC-3′
PCR: polymerase chain reaction; hVEGF: human vascular endothelial growth factor; CMV: cytomegalovirus; HPRT: hypoxanthine guanine phosphori-
bosyltransferase.
All assays are from Life Technologies.
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and used as a microvascular loop between the femoral artery 
and vein in the contralateral leg. End-to-side anastomoses 
were performed with 11/0 nylon sutures on both recipient 
artery and vein. The AVL was created on a collagen-based 
template, and a muscular flap from the pectineus muscle 
was inserted in close proximity and transduced by rAAVs. 
The muscle was chosen as a target tissue due to the high 
tropism of rAAV, serotype 2, for the skeletal muscle. The 
described chamber was then closed folding the template on 
itself and suturing its free margins together. In order to con-
firm the presence of the injected vectors within the chamber, 
we analysed DNA extracted from the samples isolated 
30 days after surgery and quantified the viral load by means 
of real-time PCR, as described in section ‘Material and 
methods’. In all the samples, we were able to detect the 
presence of rAAV genomes, as reported in Figure 1(D). 
Moreover, we analysed the expression of the transgene, and 
we could detect the expression of human VEGF in the AAV-
VEGF165 samples as reported in Figure 1(E).
AAV-VEGF165 angiogenic effect within the tissue 
chamber
The transgene expression analysis confirmed the expres-
sion of human VEGF in the pectineus muscle within the 
chamber. Therefore, to assess the functional effect of rAAV 
transduction, a histological analysis was performed on the 
muscular flap in order to check for the angiogenic response 
induced by VEGF165 overexpression. As previously 
reported by our group, VEGF165 is able to induce the forma-
tion of small arterioles that can be visualized by an immu-
nofluorescence staining for α-SMA.16,20,23 Interestingly, the 
muscular tissue was preserved intact inside the collagen 
implant and the angiogenic effect of VEGF165 could be con-
firmed by the presence of α-SMA-positive vessels sur-
rounding the muscle fibres; AAV-LacZ-injected samples 
were used as controls (Figure 1(F)).
Induction of new tissue formation
The detection of the rAAV DNA within the chamber and the 
angiogenic effect observed in the muscular flap suggested 
the feasibility of our combined tissue engineering–gene 
therapy approach. Thereby, in order to assess whether the 
expression of VEGF165 by the transduced muscle fibres 
might improve the formation of new tissue within the cham-
ber, we performed an Azan trichrome staining and quanti-
fied the newly formed tissue by means of ImageJ software.
The samples were harvested at 1 month, time not suffi-
cient for complete matrix collagen degradation; indeed, 
trabeculae were still detectable in all the samples, filling 
almost 20% of the section area. Due to the presence of the 
original collagen matrix, we were not able to quantify 
solely the newly formed tissue; instead we quantified the 
whole area occupied by the original matrix and the newly 
deposited tissue. Our quantification confirmed the data 
reported in the first described AVL model; indeed, in the 
samples with no muscle flap, the tissue filled 65% of the 
area, whereas in the AAV-LacZ group it raised up to 72% 
and in the AAV-VEGF165 group it reached 80% of the sec-
tion area (p < 0.05 AAV-LacZ vs control; p < 0.001 AAV-
VEGF165 vs control; p < 0.01 AAV-VEGF165 vs AAV-LacZ). 
Representative images and quantification are reported in 
Figure 2. Surprisingly, the muscle flap injected with AAV-
LacZ was also able to exert an effect on the chamber envi-
ronment, leading to an increase in tissue formation but not 
at the same extent as observed upon transduction with 
AAV-VEGF165. A further histological analysis of the sam-
ples allowed us to obtain an accurate characterization of 
the newly formed tissue. The quantification of the number 
of cells present within the chamber, performed by quanti-
fying the relative area occupied by DAPI nuclear staining, 
showed an increase in both the AAV-treated groups com-
pared to the control one (7.84% ± 0.63% for control, 
10.72% ± 0.52% for AAV-LacZ and 13.81% ± 0.55% for 
AAV-VEGF165; p < 0.001 AAV-VEGF165 vs control; 
p < 0.05 AAV-VEGF165 vs AAV-LacZ). Representative 
images and quantification are reported in Supplementary 
Figure 1.
These results suggest that the presence of the muscle 
flap might contribute to new tissue formation by secreting 
growth factors. Moreover, muscle transduction by AAV-
VEGF165 is able to further enhance it.
Vessel formation is improved by VEGF165 
overexpression
The Azan trichrome staining also allowed us to detect a 
consistent number of new vessels interspersed within the 
collagen trabeculae of the artificial tissue (Figure 2(A)). To 
assess whether new tissue formation might be associated or 
even favoured by an increased blood supply, as already 
showed in previous AVL models,14 we analysed the pres-
ence of α-SMA-positive vessels by immunofluorescence 
staining, which showed that many new small arterioles 
were indeed contributing to the perfusion of the tissue 
chamber (Figure 3(A)). A quantitative analysis revealed a 
pronounced increase in the number of vessels present 
within the chamber: 2.22 ± 0.24 vessels per section were 
detected in the control group, while 4.93 ± 0.42 and 
8.27 ± 0.50 vessels per section were detected in AAV-LacZ- 
and AAV-VEGF165-treated animals, respectively (p < 0.05 
AAV-LacZ vs control; p < 0.05 AAV-VEGF165 vs control; 
p < 0.05 AAV-VEGF165 vs AAV-LacZ) (Figure 3(B)).
Although not observed in all samples at the same extent, 
the angiogenic effect in some sections was impressive, 
especially in close proximity to the vein graft. As reported 
in Figure 3(C), the analysis of serial sections revealed that 
more than 10 vessels per section were detected only in the 
AAV-VEGF165 group, whereas in the AAV-LacZ group 
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vessels were always fewer. Interestingly, in some of the 
AAV-VEGF165 sample sections, we observed the presence 
of few enlarged vessels, with a thin α-SMA cell layer and 
characterized by an irregular shape, resembling vascular 
lacunae, previously described by our group16,23 (Figure 4).
To confirm that the α-SMA-positive structures were 
indeed vessels, a lectin staining was performed for the 
identification of endothelial cells. As shown in 
Supplementary Figure 2, an inner layer of endothelial cells 
can be observed in close proximity to the α-SMA-positive 
structures and the vessel lumen can be recognized. 
Interestingly, the lectin staining highlighted the presence 
of endothelial cells not surrounded by α-SMA-positive 
cells, thus suggesting the presence of capillaries. Therefore, 
we performed a further histological analysis on the tissue 
sections for the identification of the different components 
of the newly formed tissue. Besides the presence of arteri-
oles revealed by the α-SMA staining (Figure 5(A)), we 
were able to detect several lectin-positive vessels suggest-
ing a strong angiogenic process (Figure 5(B)). The newly 
formed vascular network was interspersed within the 
newly deposited collagen matrix and several cell nuclei 
were detected, as reported in Figure 2 and 3. Thereby, we 
wondered whether fibroblasts were a cellular population 
composing the new tissue. Thus, a vimentin staining was 
performed and highlighted a massive presence of fibro-
blasts suggesting an important role in tissue formation 
(Figure 5(C)).
Discussion
In medicine, the research of alternative sources for tissue 
substitutes and innovative approaches to enhance tissue 
regeneration is a major challenge. Tissue engineering has 
largely spread out in this respect, and one of the key issues 
that is emerging nowadays is the demand for vasculariza-
tion of the new templates in order to improve cell and tis-
sue survival.
Several approaches aimed to enhance the formation of 
new vascularized tissue have been described so far, and 
recently, Morrison and colleagues showed that a micro-
surgical AVL-based method could lead to the formation of 
a highly vascularized tissue within a biological scaffold. 
Indeed, these authors reported that the insertion of an AVL 
Figure 2. The presence of a muscular flap within the chamber enhances the formation of new tissue. (A) Azan trichrome staining 
of tissue chambers from control (insets a and b), AAV-LacZ-treated animals (insets c and d) and AAV-VEGF165-treated animals 
(insets e and f). The staining showed the formation of tissue within the chamber. The presence of the muscular flap was able to 
increase tissue formation (insets c and d), and it was further increased upon VEGF165 overexpression (insets e and f). Vessels can 
be identified and are shown by arrows (insets b, c and d). Scale bar = 100 µm. (B) Quantification of the area occupied by tissue; it 
is expressed as percentage of the total area. The samples were withdrawn 30 days after surgery, time not sufficient for collagen 
trabeculae degradation; thus, they were still detectable and occupied about 20% of the total area, as reported in the plot by the 
dashed line. Data are expressed as mean ± SEM. *p < 0.05, ***p < 0.001 versus control; ##p < 0.05 versus AAV-LacZ group.
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into a fibrin-rich tissue chamber enhances the formation 
of a vascularized soft tissue that resembles a connective 
tissue.13
More recently, a novel microsurgical model has been 
described, based on the usage of a commercially available 
cross-linked collagen/glycosaminoglycan (GAG) template 
Figure 3. Tissue formation, sustained by VEGF165 overexpression, entails on the induction of a strong angiogenic response. (A) 
Representative images from control, AAV-LacZ and AAV-VEGF165 samples. Sections were stained for α-SMA (red) and nuclei were 
counterstained with DAPI (blue) (insets a, d and g). Split α-SMA and DAPI signals are shown in the small panels b, c, e, f, h and i on 
the right side of the respective merged pictures. Scale bar = 50 µm. (B) Quantitative evaluation of the vascular parameter 
α-SMA-positive vessel number. Data are expressed as mean ± SEM. *p < 0.05, ***p < 0.001 versus control; ##p < 0.01 versus 
AAV-LacZ group. (C) The angiogenic response was also analysed taking into account the distribution of vessels per section. The 
histograms show the distribution of vessels per section, with a normal distribution curve superimposed. The distribution, in 
the AAV-VEGF165 group (right side), skewed towards the right compared to the AAV-LacZ group (left side) and also included a 
significant number of sections with more than 10 vessels.
Figure 4. VEGF165 overexpression induces the formation of enlarged vessels. Images from AAV-VEGF165 samples. Sections were 
stained for α-SMA (red) and nuclei were counterstained with DAPI (blue) (insets a, d, g and j). Split α-SMA and DAPI signals are 
shown in the small panels b, c, e, f, h, i, k and l on the right side of the respective merged pictures. Enlarged vessels characterized by 
a thin layer of α-SMA-positive cells are shown by arrows. The presence of erythrocytes inside the vessels can be appreciated from 
higher magnification images (insets g and j). Scale bar = 50 µm.
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as a new type of matrix to envelop an AVL in the rat groin.14 
Of interest, in this model the process of angiogenesis has 
been deeply characterized, and tensional and shear stress 
forces were shown to be the key factors for the angiogenic 
stimuli.4
In order to improve this previous model and to foster ves-
sel formation by the expression of angiogenic factors, such 
as VEGF, we took advantage of the gene transfer technology 
based on rAAV vectors. Indeed, a muscle pedicle, which is a 
suitable candidate for rAAV transduction,24,25 was inserted 
inside the collagen/GAG scaffold. For this purpose, in our 
new surgical model, we chose the pectineus muscle, which is 
close to both the loop and the chamber, in the rat groin. In 
addition, it was also selected due to its vascular and anatomi-
cal features. Thus, the muscular flap was inserted in the col-
lagen/GAG implant, still connected to the circulation by a 
vascular pedicle that ensures tissue perfusion and long-term 
survival, features needed for transgene expression by the 
muscle fibres. At 1 month after surgery, we were able to 
recover collagen/GAG implants in which the muscle flap tis-
sue was still intact and connected to the vasculature. 
Furthermore, the presence of rAAV genomes and the expres-
sion of the transgene could be detected; we also observed a 
strong angiogenic response in the muscle, as previously 
reported in other models.16,21,23,26
To better characterize our collagen chamber, we ana-
lysed the newly formed tissue and we observed a slight 
improvement in the tissue area in the presence of the mus-
cle flap injected with a control vector, which was even 
increased upon VEGF165 expression. Surprisingly, an 
increase in the new tissue area was also detected in the 
AAV-LacZ samples, and this effect might be due to the 
expression of proangiogenic factors, such as VEGF, in 
response to hypoxia by the muscular flap within the cham-
ber.27–29 Moreover, we observed that the extension of the 
area occupied by the new tissue correlated with the forma-
tion of α-SMA-positive vessels within the chamber. Indeed, 
newly formed vessels were detected in both LacZ and 
Figure 5. Characterization of the cellular populations within the newly formed tissue. (A) Representative images from AAV-
VEGF165 samples. Sections were stained for α-SMA (red) and nuclei were counterstained with DAPI (blue) (insets a and d). Split 
α-SMA and DAPI signals are shown in the small panels b, c, d and e on the right side of the respective merged pictures. Higher 
magnification images are reported in insets d, e and f. Scale bar = 50 µm. (B) Representative images from AAV-VEGF165 samples. 
Sections were stained by lectin (green) and nuclei were counterstained with DAPI (blue) (insets a and d). Split lectin and DAPI 
signals are shown in the small panels b, c, d and e on the right side of the respective merged pictures. Higher magnification images 
are reported in insets d, e and f. Scale bar = 50 µm. (C) Representative images from AAV-VEGF165 samples. Sections were stained for 
vimentin (red) and nuclei were counterstained with DAPI (blue) (insets a and d). Split vimentin and DAPI signals are shown in the 
small panels b, c, d and e on the right side of the respective merged pictures. Higher magnification images are reported in insets d, e 
and f. Scale bar = 50 µm.
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VEGF165 expressing chambers, with a stronger effect in the 
VEGF165-treated animals, confirming the notion that, also 
in this model, VEGF exerts an angiogenic effect. A more 
detailed analysis on the vasculature showed that in the pres-
ence of VEGF the number of arterioles per section was 
increased, supporting and enhancing the finding that VEGF 
is an angiogenic factor, and in agreement with data previ-
ously reported in other mouse models.16,23 A characteriza-
tion of the cellular populations composing the new tissue 
revealed the presence of endothelial cells suggesting an 
ongoing angiogenic process and the massive presence of 
fibroblasts which might be involved in matrix deposition.
Additionally, we reported the presence of some enlarged 
vessels, resembling the vascular lacunae observed previ-
ously in the VEGF-treated muscles,16,23 suggesting that the 
process of angiogenesis is mainly driven by VEGF in the 
described model.
Of notice, a strong angiogenic effect was observed not 
only in close proximity to the transduced muscle, likely 
sustained by the secreted factor, thus suggesting that the 
muscular flap might act as a bioreactor for secreted factors 
upon rAAV transduction.
Conclusion
The results obtained in this animal model confirmed the fea-
sible use of AAV-VEGF165 as a tool to enhance the formation 
of new tissue within an in vivo chamber for tissue engineer-
ing. Moreover, the increased number of α-SMA-positive ves-
sels in the VEGF-treated animals suggested that the formation 
of new tissue might entail on the angiogenic process.
Our regeneration chamber looks as a promising tool in 
tissue engineering, particularly as it acts as an isolated 
chamber, which does not allow interference from the sur-
rounding tissues. The creation of a highly vascularized tis-
sue chamber which can be microsurgically transferred to 
another site, due to the presence of a vascular pedicle, 
might be appealing for reconstructive surgery.
As a future perspective, our chamber might be envi-
sioned as a bioreactor and might be viewed as a tissue 
chamber for the in vivo expansion and differentiation of 
cells potentially enriched in precursor or stem cells.
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